# A Dose-Escalation Study of RO5083945 in Patients With Metastatic and/or Locally Advanced Malignant Epidermal Growth Factor Receptor (EGFR)+ Solid Tumors.

> **NCT00721266** · PHASE1 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 102 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** RO5083945

## Key facts

- **NCT ID:** NCT00721266
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2011-06
- **Final completion:** 2011-06
- **Target enrollment:** 102 (ACTUAL)
- **Last updated:** 2016-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00721266

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00721266, "A Dose-Escalation Study of RO5083945 in Patients With Metastatic and/or Locally Advanced Malignant Epidermal Growth Factor Receptor (EGFR)+ Solid Tumors.". Retrieved via AI Analytics 2026-08-24 from https://api.ai-analytics.org/clinical/NCT00721266. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*